Abstract:Ovarian cancer (OC) is an aggressive malignancy characterized by a complex immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy by reactivating the antitumor immune response suppressed by tumor cells. However, in the case of OC, these inhibitors have failed to demonstrate significant improvements in patient outcomes, and existing biomarkers have not yet identified promising subgroups. Consequently, there remains a pressing need to understand the interplay between OC tumor cells and their surrounding microenvironment to develop effective immunotherapeutic approaches. This review aims to provide an overview of the OC TME and explore its potential as a therapeutic strategy. Tumor-infiltrating lymphocytes (TILs) are major actors in OC TME. Evidence has been accumulating regarding the spontaneous TILS response against OC antigens. Activated T-helpers secrete a wide range of inflammatory cytokines with a supportive action on cytotoxic T-cells. Simultaneously, mature B-cells are recruited and play a significant antitumor role through opsonization of target antigens and T-cell recruitment. Macrophages also form an important subset of innate immunity (M1-macrophages) while participating in the immune-stimulation context. Finally, OC has shown to engage a significant natural-killer-cells immune response, exerting direct cytotoxicity without prior sensitization. Despite this initial cytotoxicity, OC cells develop various strategies to induce an immune-tolerant state. To this end, multiple immunosuppressive molecules are secreted to impair cytotoxic cells, recruit regulatory cells, alter antigen presentation, and effectively evade immune response. Consequently, OC TME is predominantly infiltrated by immunosuppressive cells such as FOXP3+ regulatory T-cells, M2-polarized macrophages and myeloid-derived suppressor cells. Despite this strong immunosuppressive state, PD-1/PD-L1 inhibitors have failed to improve outcomes. Beyond PD-1/PD-L1, OC expresses multiple other immune checkpoints that contribute to immune evasion, and each representing potential immune targets. Novel immunotherapies are attempting to overcome the immunosuppressive state and induce specific immune responses using antibodies adoptive cell therapy or vaccines. Overall, the OC TME presents both opportunities and obstacles. Immunotherapeutic approaches continue to show promise, and next-generation inhibitors offer exciting opportunities. However, tailoring therapies to individual immune characteristics will be critical for the success of these treatments.

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Targeting the immune microenvironment for ovarian cancer therapy

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors

Targeting tumor microenvironment in ovarian cancer: Premise and promise.

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy

The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer

Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer

Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer

Recent advances in understanding the immune microenvironment in ovarian cancer

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.

Targeting Receptor Tyrosine Kinases in Ovarian Cancer: Genomic Dysregulation, Clinical Evaluation of Inhibitors, and Potential for Combinatorial Therapies

Abstract 163: Role of macrophages in the development of ovarian cancer stem-like cells during chemotherapy

Tumor-Associated Macrophages (tams): A Critical Activator in Ovarian Cancer Metastasis

Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges

Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction

Targeting of TAMs: can we be more clever than cancer cells?

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy